Overview

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

Status:
Completed
Trial end date:
2001-07-01
Target enrollment:
Participant gender:
Summary
This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under non-fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Fluoxetine